Prostate cancer in germline BRCA2 carriers appears to occur at an earlier age; has a more aggressive phenotype, a higher risk of nodal involvement, and distant metastasis; and is associated with a poor survival outcome in comparison to noncarriers. Here, BRCA2 is linked to prostate cancer.